Litcius/Paper detail

Identified human breast milk compositions effectively inhibit SARS-CoV-2 and variants infection and replication

Xinyuan Lai, Yanying Yu, Wei Xian, Fei Ye, Xiaohui Ju, Yuqian Luo, Huijun Dong, Yi‐Hua Zhou, Wenjie Tan, Hui Zhuang, Tong Li, Xiaoyun Liu, Qiang Ding, Kuanhui Xiang

2022iScience35 citationsDOIOpen Access PDF

Abstract

The global pandemic of COVID-19 caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection confers great threat to public health. Human breast milk is a complex nutritional composition to nourish infants and protect them from different kinds of infectious diseases including COVID-19. Here, we identified that lactoferrin (LF), mucin1 (MUC1), and α-lactalbumin (α-LA) from human breast milk inhibit SARS-CoV-2 infection using a SARS-CoV-2 pseudovirus system and transcription and replication-competent SARS-CoV-2 virus-like-particles (trVLP). In addition, LF and MUC1 inhibited multiple steps including viral attachment, entry, and postentry replication, whereas α-LA inhibited viral attachment and entry. Importantly, LF, MUC1, and α-LA possess potent antiviral activities toward variants such as B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), and B.1.617.1 (kappa). Taken together, our study provides evidence that human breast milk components (LF, MUC1, and α-LA) are promising antiviral and potential therapeutic candidates warranting further development for treating COVID-19.

Topics & Concepts

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Replication (statistics)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakBreast milkVirologyHuman breast milkViral replicationBiologyMedicineComputational biologyVirusInfectious disease (medical specialty)Internal medicineDiseaseBiochemistryOutbreakCOVID-19 Impact on ReproductionInfant Nutrition and HealthSARS-CoV-2 and COVID-19 Research
Identified human breast milk compositions effectively inhibit SARS-CoV-2 and variants infection and replication | Litcius